242PClinical validation of CanAssist breast in a Spanish cohort

ConclusionsCAB performs well in stratifying risk of recurrence in this Spanish cohort with the data matching performance shown earlier with the mix of Asian and Caucasian patients. In the absence of any inter-mediate risk category in CAB, it offers a cost effective alternative to existing prognostic tests providing definitive results to plan treatment of early stage breast cancer patients.Legal entity responsible for the studyManjiri M. Bakre.FundingHas not received any funding.DisclosureM. Bakre: Leadership role, Full / Part-time employment, Officer / Board of Directors, CEO and Founder: OncoStem Diagnostics Pvt Limted.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research